Business Wire

Oral‑B Announces The Big Rethink 2026 , Launching One of Europe’s Largest Disability‑Focused Oral Health Studies

13.5.2026 10:06:00 EEST | Business Wire | Press release

Share

Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Health (iADH). The new phase introduces Project Steady, one of Europe’s largest real‑world studies exploring oral care experiences among people with disabilities, their carers and dental professionals. The programme aims to reduce everyday barriers to oral care through inclusive design, evidence-based research and professional education.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511175864/en/

Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Health Studies

Oral health for Whole-Body Health

Since its launch in 2022, The Big Rethink has been grounded in a clear belief: oral health is fundamental to whole‑body health, confidence and quality of life. For people with disabilities, barriers to daily oral care can have wider health and social implications - making inclusion an essential part of improving oral health outcomes.

The mouth is the gateway to the body and therefore acts as a mirror to your overall health. According to the World Health Organisation (WHO) oral disease affects nearly 3.5 billion people,1 Oral-B is on a mission to make the invisible connection between oral health and whole body health visible and to empower people to take their health into their own hands.

A growing and unequal challenge

New research from the Oral-B European Disability Study 2025 reveal that 41% of Europeans identify as living with a disability, representing a four‑point increase wave‑on‑wave2, driven by a broader range of visible and invisible conditions. Based on a survey of more than 9,000 adults across nine European markets3, the findings reveal a significant disparity in daily oral care experiences.

  • 52% of people with physical disabilities and 63% people with cognitive disabilities report struggling with oral care, compared with 33% of non‑disabled people. These gaps highlight the need for oral health systems, services and tools to better reflect the realities of everyday life4.

Project Steady: One of Europe’s largest real‑world oral health studies

At the heart of The Big Rethink 2026 is a six‑month, multi‑country study gathering real‑world feedback from people with disabilities, their carers and dental professionals across Europe. The study known as Project Steady represents the next wave of The Big Rethink, focused on understanding lived experience and identifying practical ways to remove everyday barriers to oral care. The Europe‑wide study builds on learnings from an earlier pilot phase led by dental professionals, which highlighted how everyday usability challenges can disrupt oral care routines.

In the pilot case study of dexterity impaired patients run in February-March 2026 in collaboration with Dr Ana Molina, 90% reduced areas with high amount of plaque after one month of using the accessory with Oral-B iO2, with 40% also showing improved gum health5.

Consumer feedback highlighted practical everyday benefits, with consumers commenting:

  • “Easier to hold and control for people with limited hand dexterity.”
  • “More comfortable brushing experience.”
  • “Helps clean more tooth surfaces and reach difficult areas.”

From insight to action

As part of the large study, participants will use Oral‑B’s iO2 electric toothbrush alongside a new adaptive accessory, designed to address two common, practical challenges to brushing:

  • Control and ergonomics - improved grip, manoeuvrability and button access
  • Stability and toothpaste application - helping prevent roll‑away and make toothpaste use easier

The expected outcomes are:

  • A more accessible brushing experience, reducing everyday usability barriers
  • Improved oral-health results, supported by real- world product performance
  • Solutions shaped directly by lived experiences, informed by participant feedback throughout the study

Oral-B Disability Champion Programme

Oral-B has recently launched a test for 200 Disability Champions across Europe to test the adaptive accessory with respective patients

Oral-B launched the Disability Champions Award Programme as part of its ongoing mission to make oral care for accessible to everybody. In partnership with the iADH, the programme aims to make the dentist office experience across Europe more inclusive and positive for those with disabilities and their caregivers.

A long-term commitment to inclusion

The Big Rethink 2026 complements Oral‑B’s ongoing initiatives:

  • Disability Champions programme, which supports more disability‑positive dental practices,
  • iADH co‑created education programme designed to help dental professionals better support patients with disabilities.

By pairing large‑scale research with inclusive design and professional education, The Big Rethink 2026 marks a decisive step in addressing barriers to oral care and supporting better whole‑body health for more people.

Paolo Grue, Senior Vice President, Oral Care Europe, Procter & Gamble, said: “We are incredibly proud to be continuing and evolving The Big Rethink. Since its launch, it has shown that oral health is not an isolated issue - it is fundamental to whole‑body health, confidence and quality of life. With Project Steady, we are building on that commitment by launching one of our most ambitious research initiatives to date listening directly to people with disabilities and translating real‑world insight into practical, inclusive solutions. This is how we create real, lasting progress. When inclusion leads, better oral health and better overall health follows."

Professor Pedro Diz Dios, President, International Association for Disability and Oral Health (iADH) said: “The link between oral health and general health is well established, yet many people with disabilities still face daily obstacles to basic oral care. Research of this scale, rooted in everyday experience, is essential if we are to develop evidence‑based solutions that genuinely improve oral health outcomes and advance health equity.”

Regina Rubio Odgers, Senior Scientist– Oral Care R&D, Oral‑B, said: “What we heard consistently through earlier phases of The Big Rethink was that small, everyday design challenges can have a significant impact on people’s ability to maintain oral care routines. This study allows us to take those insights into real‑world testing -ensuring solutions are shaped by lived experience and designed to work in everyday life.”

Dr. Ana Molina, Dental Professional and Clinical Lead, Oral‑B Pilot Study, said: “Running the pilot study showed us how small, practical barriers can quickly disrupt daily oral care routines. By testing solutions in real‑world conditions with patients and carers, we were able to generate insights that are directly relevant to both clinical practice and product development. This next phase allows those learnings to be scaled and strengthened.”

About Oral-B

Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About the International Association for Disability and Oral Health (iADH)

The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.

1Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)
2 2025 base n=9085; Showing data from Oral-B European Disability Study 2025; Increases and Decreases wave-on-wave are highlighted – these are from comparisons against data collected between 2021 and 2023
3 2025 base n=9085; Showing data from Oral-B European Disability Study 2025; Increases and Decreases wave-on-wave are highlighted – these are from comparisons against data collected between 2021 and 2023
4 2025 base n=9085; Showing data from Oral-B European Disability Study 2025; Increases and Decreases wave-on-wave are highlighted – these are from comparisons against data collected between 2021 and 2023
5 Oral-B Pilot Case Study report

View source version on businesswire.com: https://www.businesswire.com/news/home/20260511175864/en/

Contacts

Dominique Kooner
dominique.kooner@pgone.co.uk, 07940034200

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 09:38:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses. Core EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY. Adjusted Fre

Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 08:20:00 EEST | Press release

1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was st

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 08:00:00 EEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis within established governance, security, and enterprise standards. "At Owkin, we believe the future of the pharmaceutical industry is agentic," said Thomas Clozel, CEO and co-founder of Owkin. "Our exper

Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 08:00:00 EEST | Press release

Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, during the signing ceremony for the strategic partnership between Phoenix Group and DC Max to launch a European AI infrastructure platform anchored by the company’s first deployment in Lyon, France. (Photo: AETOSWire) The project is the inaugural deployment of Phoenix's European Data Center Platform, a scalable framework targeting over 1GW of combined AI and HPC capacity across Europe and the GCC. Phoenix sees this move as a direct extension of the UAE’s national AI ambition, an Abu Dhabi-headquartered company bringing it

Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 20:39:00 EEST | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye